Asceneuron’s tau modifier receives Orphan Drug Designation

20.7.2018 The US Food and Drug Administration has granted Orphan Drug Designation to Asceneuron’s ASN120290 for the treatment of progressive supranuclear palsy, a rapidly progressing rare neurodegenerative disorder. The molecule has the potential to become a first in class treatment for PSP and other tau-related dementias.

read more…